Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. (September 2021)

• Record Type: Journal Article
• Authors: Nambiar, Anoop M.; Walker, Christopher M.; Sparks, Jeffrey A.
• Is Part Of: Therapeutic advances in respiratory disease. Volume 15(2021)
• Publication Date: 2021-09
• Subjects: connective tissue diseases -- pulmonary fibrosis -- pulmonary function tests -- treatment outcome; Respiratory organs -- Diseases -- Periodicals; Respiratory agents -- Periodicals; Pulmonary pharmacology -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System Agents -- therapeutic use -- Periodicals; Respiratory Tract Diseases -- drug therapy -- Periodicals; Lung Diseases -- drug therapy -- Periodicals; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Agents respiratoires -- Périodiques; Pharmacologie pulmonaire -- Périodiques; 616.2005
• DOI: 10.1177/17534666211039771
• Languages: English
• ISSNs: 1753-4658

Abstract

Close monitoring of patients with fibrosing interstitial lung diseases (ILDs) is important to enable prompt identification and management of progressive disease. Monitoring should involve regular assessment of physiology (including pulmonary function tests), symptoms, and, when appropriate, high-resolution computed tomography. The management of patients with fibrosing ILDs requires a multidisciplinary approach and should be individualized based on factors such as disease severity, evidence of progression, risk factors for progression, comorbidities, and the preferences of the patient. In this narrative review, we discuss how patients with fibrosing ILDs can be effectively monitored and managed in clinical practice.